Data on long-term outcomes of patients with myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G (IgG)–associated disorder (MOGAD) are scarce.1,2 We report outcomes in a single-institution cohort with long-term follow-up.
We retrospectively identified 11 adult and 18 pediatric (onset age younger than 18 years) Mayo Clinic patients from January 1, 2000, through May 31, 2019, with (1) MOGAD clinical phenotype3; (2) MOG-IgG 1 seropositivity (median titer, 1:100; range, 1:20-1:1000; 8 of 13 serial samples persistently positive)3; and (3) 9 or more years’ follow-up from onset. The study was approved by the Mayo Foundation Institutional Review Board (IRB No. 08.006647). Written informed consent was provided by patients or parents.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Lopez-Chiriboga AS, Sechi E, Buciuc M, et al. Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G–Associated Disorder. JAMA Neurol. 2020;77(12):1575–1577. doi:10.1001/jamaneurol.2020.3115
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: